Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income from Continuing Operations (2021 - 2025)

Prime Medicine filings provide 5 years of Income from Continuing Operations readings, the most recent being 47525000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 12.42% to 47525000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 204838000.0, a 4.57% decrease, with the full-year FY2025 number at 204201000.0, down 4.25% from a year prior.
  • Income from Continuing Operations hit 47525000.0 in Q4 2025 for Prime Medicine, up from 52832000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 16412000.0 in Q3 2021 to a low of 65643000.0 in Q4 2023.
  • Median Income from Continuing Operations over the past 5 years was 46643000.0 (2024), compared with a mean of 44444277.78.
  • The widest YoY moves for Income from Continuing Operations: up 37.56% in 2022, down 78.83% in 2022.
  • Prime Medicine's Income from Continuing Operations stood at 62911000.0 in 2021, then surged by 37.56% to 39283000.0 in 2022, then tumbled by 67.1% to 65643000.0 in 2023, then surged by 35.6% to 42276000.0 in 2024, then decreased by 12.42% to 47525000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 47525000.0 (Q4 2025), 52832000.0 (Q3 2025), and 52591000.0 (Q2 2025) per Business Quant data.